Fresh off a splashy obesity deal, Zealand Pharma is doubling down on its R&D ambitions with a new chief scientific officer.

China’s biopharmaceutical sector is showing signs of revival from its post-pandemic slump, even as its US counterpart remains ...

Summit Therapeutics and Akeso said their PD-1xVEGF bispecific antibody ivonescimab beat BeiGene’s PD-1 blocker Tevimbra in a ...

Repertoire Immune Medicines makes a major announcement in April. And this year is no different. The Flagship ...

A small Northwestern University spinout attempting to develop a twist on biologics has pulled together a $30 million Series A ...

Ascletis Pharma's obesity drug ASC30 shows puzzling results in Phase 1b trial, with high dose less effective than lower doses ...

Eli Lilly on Thursday filed lawsuits against four telehealth companies over their sale of compounded versions of the GLP-1 ...

Telenutrition platform Nourish has raised $70 million and reached profitability a little more than a year after its last ...

Boehringer Ingelheim has inked a research collaboration with Tessellate Bio to develop precision medicines for cancers that ...

Fujifilm Diosynth Biotechnologies' bet on its North Carolina biologics facility is paying off, as Regeneron plans to shell ...

British drugmaker AstraZeneca is rejoining the drug industry's major US lobbying group, PhRMA, roughly two years after ...

The FDA has asked Novavax to commit to producing post-marketing data of its Covid vaccine, the clearest example yet that the bar is higher for advancing new vaccines under HHS Secretary Robert F.